<span item_type="fundamental" item_id="3988f6fb0d3ddc93d9824d7054f74513" counter_id="ST/US/TBRG" env="prod"></span><span item_type="announcement" item_id="646205046308933505" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 86.27 M, missing the estimate of USD 88.23 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD 0.03, missing the estimate of USD 0.2556.</p><p>EBIT: As of FY2026 Q1, the actual value is USD 5.534 M.</p><p></p><h3>First Quarter 2026 Financial Highlights (Unaudited)</h3><h4>Total Revenue</h4><p>TruBridge, Inc.’s total revenue was $86,271 thousand for the three months ended March 31, 2026, compared to $87,208 thousand for the same period in 2025. Recurring revenue constituted 94% of total revenue. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p><h4>Segment Revenue</h4><p>Revenue for the Financial Health segment was $53,274 thousand in Q1 2026, a decrease from $56,133 thousand in Q1 2025. The Patient Care segment’s revenue increased to $32,997 thousand in Q1 2026, from $31,075 thousand in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p><h4>Revenue Composition</h4><p>Total recurring revenues were $80,870 thousand in Q1 2026, down from $81,970 thousand in Q1 2025. Financial Health recurring revenues were $52,321 thousand in Q1 2026, compared to $55,263 thousand in Q1 2025, while Patient Care recurring revenues increased to $28,549 thousand in Q1 2026 from $26,707 thousand in Q1 2025. Total non-recurring revenues were $5,401 thousand in Q1 2026, up from $5,238 thousand in Q1 2025. Financial Health non-recurring revenues were $953 thousand in Q1 2026, compared to $870 thousand in Q1 2025, and Patient Care non-recurring revenues were $4,448 thousand in Q1 2026, compared to $4,368 thousand in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p><h4>Operating Income</h4><p>Operating income for Q1 2026 was $3,058 thousand, a decrease from $8,160 thousand for Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p><h4>Net Income</h4><p>GAAP net income was $506 thousand for Q1 2026, compared to $459 thousand for Q1 2025. Non-GAAP net income was $8,523 thousand for Q1 2026, an increase from $5,150 thousand for Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p><h4>Adjusted EBITDA</h4><p>Total Adjusted EBITDA was $16,474 thousand for Q1 2026, down from $18,231 thousand for Q1 2025. Segment-wise, Financial Health Adjusted EBITDA was $7,662 thousand in Q1 2026, compared to $11,281 thousand in Q1 2025. Patient Care Adjusted EBITDA was $8,812 thousand in Q1 2026, up from $6,950 thousand in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p><h4>Operating Costs</h4><p>Total expenses were $83,213 thousand for Q1 2026, compared to $79,048 thousand for Q1 2025. Costs of revenue (exclusive of amortization and depreciation) totaled $38,348 thousand in Q1 2026, compared to $39,513 thousand in Q1 2025. Product development expenses were $7,445 thousand in Q1 2026, compared to $8,247 thousand in Q1 2025. Sales and marketing expenses were $6,388 thousand in Q1 2026, compared to $5,409 thousand in Q1 2025. General and administrative expenses were $24,162 thousand in Q1 2026, compared to $19,464 thousand in Q1 2025. Amortization was $6,599 thousand in Q1 2026, compared to $6,124 thousand in Q1 2025. Depreciation was $271 thousand in Q1 2026, compared to $291 thousand in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p><h4>Cash Flow</h4><p>Net cash provided by operating activities increased to $15,452 thousand for Q1 2026, from $5,760 thousand for Q1 2025. Net cash used in investing activities was -$2,721 thousand for Q1 2026, compared to -$2,232 thousand for Q1 2025. Net cash used in financing activities was -$2,162 thousand for Q1 2026, compared to -$5,728 thousand for Q1 2025. Cash and cash equivalents at the end of the period were $35,419 thousand as of March 31, 2026, up from $10,124 thousand as of March 31, 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p><h4>Other Key Metrics</h4><p>Total Bookings (Annual Contract Value - ACV) were $17,650 thousand for Q1 2026, compared to $17,340 thousand for Q1 2025. Financial Health bookings were $12,463 thousand in Q1 2026, compared to $12,780 thousand in Q1 2025, while Patient Care bookings were $5,187 thousand in Q1 2026, compared to $4,560 thousand in Q1 2025. TruBridge, Inc. reports bookings on an Annual Contract Value (ACV) basis, representing newly contracted revenue expected to be recognized over a twelve-month period, effective January 2026. Total assets were $407,539 thousand as of March 31, 2026, compared to $402,528 thousand as of December 31, 2025. Total liabilities were $228,851 thousand as of March 31, 2026, compared to $224,567 thousand as of December 31, 2025. Total stockholders’ equity was $178,688 thousand as of March 31, 2026, compared to $177,961 thousand as of December 31, 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p><h4>Outlook / Guidance</h4><p>TruBridge, Inc. has entered into a definitive agreement to be acquired by Inventurus Knowledge Solutions, Inc. (IKS) for $26.25 in cash per share of common stock. The transaction is anticipated to close during the third calendar quarter of 2026, subject to shareholder and regulatory approvals. Due to this pending transaction, TruBridge, Inc. will not host a conference call or webcast for its first quarter 2026 financial results. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1169445/000143774926015921/ex_959464.htm"></span></p>

TruBridge | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 86.27 M